Paradigm Therapeutics

Paradigm Therapeutics is a privately-held clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. Paradigm primarily concentrates on the treatment of Epidermolysis Bullosa (EB). SD-101, its leading therapy for treating the skin effects in patients with Epidermolysis Bullosa, has completed Phase II and Phase III clinical trials. SD-101 is a topical cream that has demonstrated potential to improve severe skin effects in patients across all EB subtypes.